Emcyt
FDA Expands Zytiga for Late-Stage Prostate Cancer »
"The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.
The FDA initially appr"...
Read the FDA Expands Zytiga for Late-Stage Prostate Cancer article »
Emcyt
PATIENT INFORMATION
Because of the possibility of mutagenic effects, patients should be advised to use contraceptive measures.
Last reviewed on RxList: 8/6/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Emcyt Information
Emcyt - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cancer
Get the latest treatment options.






